{
  "study_metadata": {
    "study_id": null,
    "design": "RCT"
  },
  "exposure": {
    "label": "resveratrol supplementation",
    "comparator": "placebo"
  },
  "outcomes": [],
  "missing_fields": [
    "outcomes"
  ],
  "evidence": [
    "Study reports 12‑week RCT of 500 mg resveratrol vs placebo in NAFLD patients.",
    "Baseline and 12‑week data presented for ALT, AST, inflammatory markers, but no FPG, HbA1c or HOMA‑IR values are shown."
  ],
  "comment": "No glycemic data reported.",
  "comment_detailed": "I searched the abstract, methods, and results for glycemic measures (FPG, HbA1c, HOMA‑IR). The study focuses on liver enzymes and inflammatory markers; no tables or text mention glucose or insulin indices. Thus, glycemic outcomes are missing. Full PDF or supplementary tables might reveal such data if collected.",
  "confidence": 0.8
}